PRINCETON, N.J.– Bristol Myers Squibb has announced the appointment of Dr. Cristian Massacesi as executive vice president, chief medical officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company’s early-stage and late-stage product development across all therapeutic areas.
“We are thrilled to welcome Cristian to Bristol Myers Squibb,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “His deep scientific expertise, strong focus on clinical execution and proven track record of regulatory approvals will be instrumental as we continue to advance our pipeline and deliver breakthrough medicines to even more patients around the world. Cristian also has a very strong track record of building and developing world-class teams.”
“I am on a mission to discover new medicines - unlocking innovative approaches to researching and treating challenging diseases so that one day, no patient will hear that all options have been exhausted. I am excited to join BMS in this shared purpose, with its storied history, vast pipeline across therapeutic areas, exceptional reputation, and culture deeply committed to making a difference,” said Dr. Massacesi.
Samit Hirawat, M.D., Bristol Myers Squibb’s Executive Vice President, Chief Medical Officer, and Head of Development for the past six years, is stepping down to pursue new professional opportunities. Dr. Hirawat will transition from his current role, effective August 1, 2025, and will remain an advisor to the Company through November 1, 2025, to ensure a seamless transition.
Boerner continued, "We sincerely thank Samit for his leadership and dedication to innovative drug development at BMS over the past six years. Under his guidance, we have advanced groundbreaking science that has culminated in the approval of many new products across oncology, hematology, immunology, cardiovascular, and neuroscience. His commitment and visionary approach have driven our progress and positioned us at the forefront of impactful medical innovation."
